However, it is known that a percentage of KRAS or NRAS WT patients is not responsive to EGFR targeted therapy, leaving to hypothesize that additional mediators could be involved in the dysregulation of molecular mechanisms leading to tumor initiation and development. This evidence concerns the gene EGFR and neoplasm.